CVS Health (CVS) stock is in negative territory Wednesday after the pharmacy chain and healthcare benefits provider reported mixed results for its second quarter and slashed its full-year profit forecast.
In the three months ended June 30, CVS said its revenue increased 2.6% year-over-year to $91.2 billion, driven by growth in its Health Care Benefits and Pharmacy & Consumer Wellness segments. However, its earnings per share (EPS) decreased 17.2% from the year-ago period to $1.83, primarily due to a decline in operating income in its Health Care Benefits segment.
"We have many points of differentiation that position us to win now and into the future," said CVS CEO Karen Lynch in a statement. "Our innovation is accelerating more transparent pharmacy reimbursement models, increasing the use of biosimilars, and providing better patient outcomes through our connected health care delivery assets."
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The results were mixed compared with what analysts were expecting. Wall Street anticipated revenue of $91.5 billion and earnings of $1.73 per share, according to Yahoo Finance.
For a second consecutive quarter, CVS reduced its full-year profit forecast. The company now anticipates earnings per share to arrive between $6.40 to $6.65, down from its previous forecast of at least $7.00. It's also guiding for cash flow from operations of approximately $9 billion, down from its previous forecast of at least $10.5 billion.
"The Company's guidance revision reflects continued pressure in the Health Care Benefits segment, partially offset by strong performance in the Health Services and Pharmacy & Consumer Wellness segments," CVS said.
Is CVS stock a buy, sell or hold?
CVS Health is down more than 20% for the year to date, but Wall Street remains bullish on the healthcare stock. According to S&P Global Market Intelligence, the consensus analyst target price for CVS stock is $67.74, representing implied upside of more than 17% to current levels. Additionally, the consensus recommendation is Buy.
Still, there are some on Wall Street that are hesitant. Financial services firm UBS Global Research, for instance, has a Neutral rating (equivalent to a Hold) and a $60 price target. And UBS analyst Kevin Caliendo issued a stern warning to investors ahead of earnings.
"It is a 'stay away' on this print," Caliendo wrote in an August 5 note. Analysts' consensus view was "challenging," he said. "The potential range of outcomes here is meaningful, thus while the stock is cheap relative to managed care peers, we have little conviction in the near-term outlook."
Related Content
-
2025 Social Security COLA Estimate Drops AgainThe final Social Security COLA estimate for 2025 has dropped slightly from the previous estimate.
-
Will a Fed Rate Cut Lower Mortgage Rates?A Federal Reserve interest rate cut, expected next week, is one of many influences on mortgage rates, along with inflation, job growth and a shrinking or thriving economy.
-
Microsoft Eliminates Another 650 Positions at Xbox GamingMicrosoft stock is down slightly after announcing another round of layoffs in its Xbox gaming division. Here's what you need to know.
-
Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to KnowModerna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.
-
Estate Planning: How to Protect Family TreasuresItems like antiques, art and jewelry, as well as family photos, can carry huge emotional ties. The more specific you are in your plans, the better for everyone.
-
529 Plans: A Powerful Way to Tackle Rising Education CostsContributions to 529 plans grow tax-free and are not taxed when they are used to pay for qualified educational expenses for the beneficiary.
-
Stock Market Today: Stocks Stagger After CPI but Rebound to Post GainsA mixed CPI report had traders recalibrating their rate-cut bets.
-
Mixed August CPI Report Seals September Rate Cut: What the Experts Are SayingCPI A good-but-not great reading on consumer inflation sets up the Fed to reduce rates by a quarter-point at its next meeting.
-
Bank of America Stock Falls As Warren Buffett Keeps SellingBank of America stock is lower Wednesday on news Warren Buffett's Berkshire Hathaway sold another chunk of its stake in the bank. Here's what you need to know.
-
Is PLAY Stock a Buy After a Dave & Buster's Earnings Beat?PLAY stock is higher Wednesday after the entertainment and restaurant chain reported strong Q2 earnings, but what does Wall Street have to say?
